Global Choroidal Neovascularization Drug Market Size By Type (AVMOC-001, BB-3), By Application (Clinic, Hospital), By Region, And Segment Forecasts, 2023 to 2032

The Global Choroidal Neovascularization (CNV) Drug Market was valued at USD 8.1 billion in 2023 and is projected to reach USD 13.6 billion by 2031, growing at a CAGR of 6.7% during the forecast period (2023–2031). CNV is a condition commonly associated with age-related macular degeneration (AMD), myopic maculopathy, and ocular histoplasmosis syndrome. The market is witnessing robust growth owing to increasing prevalence of AMD and other retinal disorders, rising geriatric population, and continuous innovations in biologics and anti-VEGF therapies.

Key market players are investing heavily in research and development for next-generation anti-angiogenic agents, combination therapies, and sustained-release delivery systems. These efforts are not only improving patient outcomes but also expanding the therapeutic landscape of CNV treatment.

Drivers:

1. Rising Incidence of Age-Related Macular Degeneration (AMD):

The growing geriatric population is directly contributing to the increased incidence of AMD, one of the primary causes of CNV. This trend significantly boosts the demand for CNV therapeutics, particularly anti-VEGF agents.

2. Technological Advancements in Drug Delivery:

Development of long-acting injectables, implantable devices, and sustained-release drug formulations are revolutionizing CNV treatment by reducing injection frequency and enhancing compliance.

3. Increase in Ophthalmic Screening Programs:

Government initiatives and awareness campaigns focusing on early detection of retinal disorders are improving diagnosis rates and creating a greater need for effective CNV treatments.

Restraints:

1. High Treatment Costs:

The cost of anti-VEGF therapies like aflibercept and ranibizumab remains a major concern, especially in low-income regions, limiting accessibility and affecting market penetration.

2. Risk of Adverse Effects:

Invasive procedures such as intravitreal injections carry risks like endophthalmitis and intraocular pressure elevation, discouraging some patients and affecting treatment adherence.

Opportunity:

1. Emergence of Biosimilars and Generics:

The patent expiry of key biologics has paved the way for biosimilars, promising cost-effective alternatives and enhancing accessibility in developing economies.

2. Expanding Research on Gene and Cell Therapy:

Innovative approaches like gene therapy and stem cell-based treatments present long-term solutions for CNV, offering lucrative opportunities for pharmaceutical companies.

Market by System Type Insights:

Based on treatment class, anti-VEGF therapy dominated the market in 2023, accounting for over 80% of total revenue. Drugs such as Ranibizumab (Lucentis) and Aflibercept (Eylea) remain the most prescribed therapies due to their proven efficacy in halting vision loss and promoting vascular stabilization.

However, the steroid-based therapy segment is witnessing gradual adoption for patients unresponsive to anti-VEGF or those with inflammatory CNV, suggesting a potential growth area over the forecast period.

Market by End-Use Insights:

The hospital pharmacies segment held the largest market share in 2023, driven by increased hospital-based treatments and intravitreal injection procedures. Meanwhile, retail pharmacies are gaining traction owing to the growing use of at-home injectables and convenience in refills.

Specialty clinics are expected to register the fastest growth rate due to the increasing number of ophthalmic centers specializing in retinal disease management.

Market by Regional Insights:

In 2023, North America led the global CNV drug market, owing to its advanced healthcare infrastructure, high disease awareness, and strong reimbursement policies. The U.S. remains a dominant contributor with a high adoption rate of biologic therapies.

Asia-Pacific is projected to witness the highest CAGR during the forecast period, driven by improving healthcare access, rapid aging population in countries like Japan and China, and increasing diagnosis rates of retinal conditions.

Competitive Scenario:

Key market players include Genentech (Roche), Regeneron Pharmaceuticals, Novartis AG, Allergan (AbbVie), Bayer AG, Kodiak Sciences, and Graybug Vision. These companies are focusing on expanding their pipelines through strategic collaborations, licensing agreements, and the development of next-gen CNV therapies.

Recent Developments:

In 2023, Roche’s Faricimab (Vabysmo) received global regulatory approvals for CNV and DME, marking a significant innovation with dual-pathway inhibition.

In 2024, Kodiak Sciences announced positive Phase III trial results for KSI-301, a long-acting anti-VEGF agent showing superior durability.

In 2025, Novartis expanded its portfolio with the acquisition of a gene therapy startup focusing on retinal vascular diseases.

Scope of Work – Global Choroidal Neovascularization Drug Market

Key Market Developments:

2023: Roche launched Vabysmo, a bispecific antibody targeting both Ang-2 and VEGF-A.

2024: Regeneron began trials for its new extended-release formulation of aflibercept.

2025: Novartis acquired EyePoint Pharmaceuticals to boost its retinal disease pipeline.

FAQs:

What is the current market size of the Global Choroidal Neovascularization Drug Market?

The market was valued at USD 8.1 billion in 2023.

What is the major growth driver of the Global Choroidal Neovascularization Drug Market?

The increasing prevalence of age-related macular degeneration is the primary growth driver.

Which is the largest region during the forecast period in the Global Choroidal Neovascularization Drug Market?

North America is expected to remain the largest regional market.

Which segment accounted for the largest market share in the Global Choroidal Neovascularization Drug Market?

The Anti-VEGF therapy segment held the largest share in 2023.

Who are the key market players in the Global Choroidal Neovascularization Drug Market?

Genentech, Regeneron, Novartis, Bayer, and Kodiak Sciences are among the key players.